

# Index

## A

- Activation-induced cytidine deaminase (AID), 209, 244
- Adaptive immune system
  - cell-mediated immunity, 244
  - components of, 234
  - CTL, 245
  - defects of, 233–234
  - and exercise (*see* Physical exercise)
  - humoral immunity, 243–244
  - skin
    - antigen-presenting cells, 343–344
    - B lymphocytes, 342
    - CD4<sup>+</sup> helper T cells, 343
    - lymphocytes, 343
    - T helper 1/T helper 2 paradigm, 343
    - T lymphocytes, 343
    - T-regulatory cells, 343
  - T helper cells, 244–245
- Adrenocorticotropic hormone (ACTH), 19, 354
- Age-related macular degeneration (AMD)
  - AGEs and RAGEs, 119
  - dry/non-neovascular, 119
  - NLRP3 inflammasome activation, 119–120
  - wet, 119
- $\alpha$ -melanocyte stimulating hormone ( $\alpha$ -MSH), 354, 355
- Alzheimer's disease
  - NLRP3 inflammasome activation, 118–119
  - TLRs, 117–118
  - Tregs, 203–204
  - vitamin E, 181
- AMD. *See* Age-related macular degeneration (AMD)
- Antibody-dependent cell cytotoxicity (ADCC), 76
- Antigen-presenting cells (APCs), 235, 244
  - DDCs, 344
  - dendritic cells (*see* Dendritic cells (DCs))
  - eosinophils, 49
  - inflammatory dendritic cell, 344
  - Langerhans cells, 343–344, 352
  - neutrophils, 51
  - plasmacytoid dendritic cells, 344, 352
  - UV exposure, 359
- Antioxidants, 14–15
- APCs. *See* Antigen-presenting cells (APCs)
- Asteatotic dermatitis, 363
- Asthma, 332
- Autoimmunity, 237

## B

- Bacterial meningitis, 235
- Basophils, 48–49
- B cell
  - factors, 207
  - hematopoietic stem cells, 207
  - IL-7 receptor, 208
  - InK4A/Arf expression, 208
  - somatic hypermutation, 208–209
  - telomere, 209
- Body mass index (BMI), 195, 277–278, 372
- Bullous pemphigoid, 364

## C

- Calorie restriction (CR), 15
  - CMV<sup>+</sup> animals, 154
  - immune response, modulation of, 289
  - mild dietary stress, 18
  - and protein nutritional status, 266
- Cancer
  - incidence of, 75
  - natural killer cell (*see* Natural killer (NK) cells)
  - pattern recognition receptors
    - AIM2 and IFI16 expression, 105–106
    - chemotherapeutics, 107–108
    - CLRs and RLRs, 115–116
    - genetic alterations, 105–106
    - inflammasomes, 104–105
    - NLR members, 105
    - pyroptosis, 105
    - TLRs, 108–115
  - skin cancer, 361, 362
- Candida albicans*, 53, 55
- Cardiovascular disease
  - NLRP3 inflammasome activation, 103–104
  - TLRs, 102–103
- Cataract, 332
- Cathelicidins, 342
- CC chemokine receptor 6 (CCR6), 341
- Cell-mediated immunity (CMI), 168, 237, 238
- Cellular ageing
  - free radical theory, 37
  - Hayflick limit, 37
  - inflamm-ageing model (*see* Inflammation)
  - mutation accumulation theory, 37

Chemokine receptor type 7 (CCR7), 68, 69, 185  
 Class switch recombination (CSR), 208, 209, 243–244  
 Copper deficiency, 269  
 CR. *See* Calorie restriction (CR)  
 Cryptococcosis, 236  
 CSR. *See* Class switch recombination (CSR)  
 Cytokines  
   cytokine genes and longevity, 223–226  
   DCs, age-associated changes in, 66–67  
   immune responses, 255–256  
   neutrophils, age-related changes in, 55–56  
   NK cells, in healthy ageing, 78  
   T-cell signaling, 383–384  
   UV exposure, 359  
 Cytomegalovirus (CMV), 236–237, 370  
   impact of, 147  
   MCMV, 150–151, 195  
   TCE, 149–150  
   therapeutic approaches, 154  
   vaccination, 155  
 Cytotoxic T-lymphocyte antigen 4 (CTLA-4), 360  
 Cytotoxic T lymphocytes (CTLs), 245, 246

## D

Damage-associated molecular patterns (DAMPs), 87, 88, 96, 98, 101, 102, 104  
 Dendritic cells (DCs), 242, 254  
   cDC and pDC population, phenotype of, 65–66  
   DDCs, 344  
   discovery of, 65  
   exercise, 374–375  
   hematopoietic stem cells, 65  
   and immunity in elderly  
     inflammasome, 68  
     innate interferon secretion, 67–68  
     TLR and cytokine secretion, 66–67  
   Langerhans cells, 66  
   and mucosal tolerance, 70  
   NK cells, 77  
   and peripheral tolerance, 69–70  
   phagocytosis and migration, 68–69  
   subsets of, 65–66  
   T cell priming, 69  
 Dermal dendritic cells (DDCs), 344  
 Dermcidin, 342  
 Diet  
   ageing process, prevention of  
     calorie restriction and modulation, 289  
     Mediterranean diet and longevity, 289–291  
   dietary intake and zinc supplementation  
     (*see* Zinc)  
   nutrition and immune system  
     gastrointestinal immunosenescence, 287–289  
     micronutrients, 286–287  
 DNA methyltransferase (DnMT), 41  
 Dysbiosis, 288

## E

Elderly population  
   bacterial meningitis, 235  
   fungal infections, 236  
   immune responsiveness, 251–252  
   influenza infection in (*see* Influenza infection)  
   nutritional deficiencies, pathological causes  
     (*see* Nutrition)  
   respiratory infections, 235  
   skin disease in (*see* Skin)  
   susceptibility of, 252  
   tuberculosis, 235–236  
   vaccination in (*see* Vaccination)  
   viral infections, 236–237  
   zinc status of, 298–299  
 Environmental enrichment (EE), 16–17  
 Eosinophils  
   age-associated changes in, 50  
   antigen-presenting cells, 49  
   cytoplasmic crystalloid granules, 49  
   immune hypersensitivity syndromes, role in, 50  
   lifespan of, 49  
   pattern recognition receptors, 50  
   tissue remodeling, 50  
 Epstein–Barr virus (EBV), 107, 149, 150, 236  
*Escherichia coli*, 232

## G

Gastrointestinal (GI) system, 272, 273  
 Glutathione sulfurtransferases  
   epoxide hydrolases, 329  
   quinone reductase, 329  
   UDP-glucuronosyl transferase, 328  
 Granulocyte-colony-stimulating factor (G-CSF), 31, 51, 299, 371  
 Granulocyte-monocyte-colony-stimulating factor (GM-CSF)  
   chemotaxis, 54  
   lifespan of, 51  
   phagocytosis and respiratory burst, 55  
   proliferation and apoptosis, 53  
   signaling pathways, 58  
 Granzyme B (GrzB), 245

## H

Hemagglutination inhibition (HI), 253, 254  
 Hematopoietic stem cells (HSCs), 65  
 High-mobility group box 1 (HMGB1), 112–113  
 Hormesis  
   biological and nutritional hormetin, 18  
   definition, 17  
   EE, 18–19  
   environmental toxins, 19  
   nutrition, effects of, 18  
   physical exercise, 18–19  
   physical hormetins, 18  
   physiological hormetins, 18

Human  $\beta$ -defensins, 341  
 Human leukocyte antigen (HLA), 76, 221–223  
 Human longevity  
   centenarian offspring, 220  
   C282Y mutation, 221  
   cytokine genes  
     functions, 223  
     IL-10 haplotype, 225  
     IL-10 polymorphisms, 224–225  
     inflammatory processes, 224  
     interleukin (IL)-6, 224  
     TGF, 225  
   estrogens, 221  
   HLA, role of, 221–223  
   human hemochromatosis, 221  
   life expectancy, in twins, 219  
   sociological factors, 220  
 Hypertension, 335  
 Hypoxia-inducible factors (HIFs), 345

## I

Immune system, 340, 350  
   adaptive immune system (*see* Adaptive immune system)  
   B and T lymphocytes, 1  
   biological age, concept of  
     age-related changes, 5–7  
     epigenetic mechanisms, 4  
     functions, 8–9  
     integrative theory, 10–11  
     murine models, prematurely ageing mice, 9  
     oxidation and inflammation, 5, 11–13  
     psychoneuroimmunoendocrine system, 7–8  
     retrospective analysis, 4–5  
   dendritic cells (*see* Dendritic cells (DCs))  
   elderly subjects, 3  
   environment and lifestyle strategies  
     environmental enrichment, 16–17  
     hormesis, 17–19  
     nutrition, 14–15  
     physical activity, 15–16  
   human longevity, 3  
   innate immune system (*see* Innate immune system)  
   mucosal immunity, 234–235  
   nutrition (*see* Nutrition)  
   research, ageing, 2  
   UV effects, cutaneous immune system, 357, 358  
 Immunoreceptor tyrosine-based activation motif (ITAM), 186  
 Immunosenescence, 47  
   definition, 231  
   and diet (*see* Diet)  
   immune risk profile, 370  
   and inflammation, 285–286  
   microRNAs  
     B-lymphocyte maturation, 215  
     DNA methylation and histone acetylation, 212–213  
     IL-6 and IL-8, 213  
     MiR-92a expression, 214  
     MiR-146a expression, 212, 213  
     neutrophils, 213–214  
     regulatory role, 211  
     thymus involution, 215  
     triple negative 1 cell transition, 214–215  
     3' untranslated region, 211  
   NK cell and cancer (*see* Natural killer (NK) cells)  
   and nutrition (*see* Nutrition)  
   role of, 246  
 Infection  
   bacterial meningitis, 235  
   clinical consequences, 232  
   epidemiologic perspective, 231–232  
   fungal infections, 236  
   immunosenescence and susceptibility, 231  
   respiratory infections, 235  
   tuberculosis, 235–236  
   viral infections, 236–237  
 Inflammation  
   acute-phase protein response, 37–38  
   epigenetic changes, role of  
     DNA methylation, 41–42  
     epigenetic histone modifications, 39  
     histone acetylation, 39–41  
     histone deacetylase enzymes, 40  
     miRNA, 42–43  
     protein acetylation, 40–41  
   macrophages, 38  
   metabolism, 38–39  
   monocytes, 38, 39  
   neutrophils, 37  
 Influenza infection  
   antigenic mismatch, 246  
   clinical presentations, 239–240  
   disability, 240  
   immune system  
     adaptive immune system (*see* Adaptive immune system)  
     innate immune system (*see* Innate immune system)  
   immunosenescence, 246  
   morbidity and mortality, 240  
   respiratory system, 240–241  
   vaccination (*see* Vaccination)  
 Influenza virus vaccine (IFV), 231  
 Innate immune system  
   Ca-dependent cellular signal transduction, 233  
   chronic diseases, 233  
   components of, 233  
   dendritic cells, 242  
   and exercise (*see* Physical exercise)  
   GM-CSF, 232, 233  
   LPS stimulation, 232  
   macrophages, 242  
   neutrophils, 241–242  
   NK cells, 242–243  
   SHP-1, 233

Innate immune system (*cont.*)

- skin
  - antimicrobial peptides, 341–342
  - complement, 341
  - keratinocytes, 342
  - NK cells, 342
  - phagocytes, 342
  - physical and chemical barriers, 341
- TLR, 232, 233, 342

Interleukin 2 (IL-2), 255

Interleukin 6 (IL-6)

- C-reactive protein, 107
- zinc-IL-6 gene interaction, 303

Interleukin 7 (IL-7), 255

Iron deficiency, 267

**K**

Keratinocytes, 340, 342

Killer immunoglobulin-like receptors (KIRs), 76

**L**

Langerhans cells (LCs), 66, 254, 343–344, 352

Lipopolysaccharide (LPS), 87, 232

Live attenuated influenza vaccines (LAIV), 256

**M**

Major histocompatibility complex (MHC), 242

Matrix metalloproteinase (MMP), 50, 58, 113, 350, 353

Mediterranean diet (MD), 289–291

Melano-cortin-1 receptor (MC1R), 354, 355

Memory T cells

- bone marrow, 167
- reactogenicity, 168

Merkel cells, 339–340, 362

Metabolic syndrome, 98–102

Metabolism

- animal models, 195–197
- autoimmune diseases, 194
- CD28/PI3K/Akt/mTOR Pathway, 188
- cholesterol levels, 195
- dendritic cells, 191
- ERR- $\alpha$ , 191
- IL-6 inflammation, 194
- immunosenescence, 190–191
- infectious diseases, 193
- lipid metabolism, 188
- nutrients/growth factor hypothesis, 188–189
- oligosaccharide synthesis, 187
- osteoporosis, 194
- RA, 194
- signalling and membrane components, 192–193
- steady state vs. activated T cells, 187–188
- surface receptors, 191–192
- in T cell subsets, 189–190
- type 2 diabetes, 194

Metallothioneins (MT)

- IL-6 polymorphisms, 303–304
- zinc-MT gene interaction, 302–303

MicroRNAs (miRNA)

- inflammation and ageing, 42–43
- TLRs, lung cancer, 112

Midarm muscle area (MAMA), 278

Midarm muscle circumference (MAMC), 278

Mini Nutritional Assessment (MNA), 274, 275

Mitogen-activated protein kinases (MAPK), 286

Mucosal immunity, 234–235

Multiple sclerosis, 334

Mycobacterium tuberculosis (MTB), 235

**N**

Natural killer (NK) cells, 233, 236, 242–243

- activating and inhibitory receptors, 76
- in cancer

- cytotoxicity, 80–81
- elderly patients, 81–82
- hematological malignancies, 79
- inhibitory and activating signals, 79
- non-Hodgkin lymphoma, 79–80
- solid tumors, 80

definition of, 76

dendritic cells, 77

in healthy elderly individuals

- cytokines, 78
- cytotoxicity, 77–78
- inflamm-aging, 78
- subsets, redistribution of, 77

macrophages, 77

subsets, 76

Neurodegenerative diseases, 332–333

Neutrophils

- age-related changes in
  - adhesion, 54–55
  - chemotaxis, 53–54
  - cytokines, 55–56
  - phagocytosis and respiratory burst, 55
  - proliferation and apoptosis, 52–53
  - signaling pathways, 56–58
- age-related diseases, 58–59
- cytokines and chemokines, 51
- as immunoregulatory cells, 51
- lifespan of, 51

Nicotinamide adenine dinucleotide phosphate (NADPH), 371

NK-cell cytotoxic activity (NKCA), 376

NK cells. *See* Natural killer (NK) cells

N-3 polyunsaturated fatty acids (PUFA), 265–266

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF $\kappa$ B), 286, 345

Nuclear factor of activated T cells (NFAT), 88

Nutrition

- anthropometric assessment, 277–278
- biochemical markers, 278, 279
- dietary intake assessment, 278, 279
- medical history
  - drug history and allergies, 276
  - family history, 276
  - past medical and surgical history, 275, 276

personal and social history, 276  
 present illness, 275, 276  
 nutritional interventions, 279–280  
   primary immunonutrition, 280  
   secondary immunonutrition, 280  
 physical examination, 276–277  
 physical factors  
   body composition, 272  
   chronic diseases, 273–275  
   GI system, 272, 273  
 primary immunosenescence  
   caloric restriction, 266  
   definition, 264  
   probiotics, 266  
   protein nutritional status, 266  
   PUFA, 265–266  
 psychological factors, 274  
 screening tools, 274, 275  
 secondary immunosenescence  
   copper deficiency, 269  
   iron deficiency, 267  
   selenium deficiency, 268, 269  
   vitamin A deficiency, 269  
   vitamin B6 deficiency, 269  
   vitamin B9 deficiency, 269–270  
   vitamin B12 deficiency, 269–270  
   vitamin C deficiency, 270  
   vitamin D deficiency, 270  
   vitamin E deficiency, 270  
   zinc deficiency, 268  
 social factors, 274  
 tertiary immunosenescence, 270–271  
   cell-mediated immunity, 271–272  
   humoral immunity, 272  
   innate immunity, 271  
 undernutrition, cycle of, 264

**O**

Oxidative stress  
 antioxidants  
   ascorbic acid/vitamin C, 325–326  
   carotenoids, 326  
   endogenous and exogenous, 325  
   flavonoids/bioflavonoids, 326  
   free radicals, 326–328  
   glutathione peroxidase, 325  
   silymarin, 326  
   SOD, 325  
   vitamin E, 325  
 apoptosis, role of, 331  
 asthma, 332  
 autoimmunity, 333–334  
 cataract, 332  
 glutathione sulfurtransferases, 328–329  
 history, 323–324  
 hypertension, 335  
 molecular mechanism of, 324–325  
 multiple sclerosis, 334  
 neurodegenerative diseases, 332–333  
 nutrition and diet, 335–336

reproduction, 334–335  
 SAPK family, 330  
 superoxide dismutases, 329–330  
 telomeres, 330–331

**P**

Pathogen-associated molecular patterns (PAMPs), 87  
 Pattern recognition receptors (PRRs)  
   age-related immune disorders  
     cancer (*see* Cancer)  
     cardiovascular disease, 102–104  
     cognition and neurodegenerative disease, 116–119  
     infections, 97–98  
     macular degeneration and retinopathy, 119–120  
     metabolic syndrome, 98–102  
 CLRs and NLRs, 88  
 eosinophils, 50  
 Janeway's theory, 87  
 PAMPs, 87  
 toll-like receptors  
   aged adults, 90–93  
   discovery of, 87  
   hyporesponsiveness, 93–94  
   in infancy, 88–90  
   inflammation, 94–97  
   vaccination of elderly, 120  
 PEM. *See* Protein–energy malnutrition (PEM)  
 Percutaneous endoscopic gastrostomy (PEG), 279  
 Peripheral blood mononuclear cells (PBMCs), 383  
 Phagocytosis  
   dendritic cells, 68–69  
   neutrophils, 55  
 Physical exercise  
   adaptive immunity  
     CD4:CD8 ratio, 382  
     regulatory, Th17, and gamma-delta T cells, 384–385  
     T-cell cytokine signaling, 383–384  
     T-cell phenotype, 377–382  
     T-cell proliferation, 382–383  
   inflamm-aging, 385–387  
   innate immunity  
     DCs, 374–375  
     monocytes/macrophages, 372–374  
     neutrophils, 370–372  
     NK cells, 375–377  
   randomized control trials, 379–381  
   training status, 378  
   vaccination, 388–389  
   viral infections, 387–388  
 Phytohemagglutinin (PHA), 382, 383  
 Plasmacytoid dendritic cells (PDCs), 344, 352  
 Polymorphonuclear leukocytes (PMNs), 341, 342  
 Probiotics, 266  
 Protein–energy malnutrition (PEM)  
   cell-mediated immunity, 271–272  
   effects of, 271  
   humoral immunity, 272  
   innate immunity, 271  
   PEM-induced lymphoid atrophy, 271  
   SENIEUR criteria, 264

Protein kinase C (PKC), 286, 287

PRRs. *See* Pattern recognition receptors (PRRs)

*Pseudomonas aeruginosa*, 232

## R

Reactive oxygen species (ROS), 287

dendritic cells

damage-associated molecular patterns, 313

innate and adaptive immune responses, 312

lipopolysaccharide, 314

NADPH oxidase, 314

signaling molecules and transcription factor, 313

environment and pollution, 312

granulocytes, 316–318

macrophages, 315–316

mitochondria, 309–310

oxidative burst, 311–312

Recommended dietary allowances (RDA), 296, 298, 299

Respiratory infections, 235

Respiratory syncytial virus (RSV), 238

Retinopathy, 119–120

ROS. *See* Reactive oxygen species (ROS)

## S

Selenium deficiency, 268, 269

Skin, 345–346

ageing mechanism

DNA damage, 345

oxidative stress, 345

telomeres, 344

basic structure and function

dermis, 340

epidermis, 339–340

subcutaneous fat, 340

drug eruptions, 364

effects of ageing, 344

immune system, 340–341, 350–351

APC, 351–352

B lymphocytes, 351

monocytes and macrophages, 352

plasmacytoid dendritic cells, 352

T lymphocytes, 351

infectious processes

bacterial infection, 363

dermatophytes and yeasts, 363

parasitic infection, 363

viral infection, 363

intrinsic skin ageing

cutaneous glands and nerves, 350

dermis, 348–349

effects of menopause, 350

epidermis, 346–348

fine wrinkling, dryness, 347

functions, 347

hair, 349

histologic features, 346

laxity and benign neoplasms, 347

subcutaneous tissue, muscles and bone, 349

papulosquamous disorders

pruritus, 363

xerosis and asteatotic dermatitis, 363

pathophysiology of, 362

photoaging

clinical features, 356

heliodermatitis, 356

mechanism and clinical findings, 353–357

UV light, 352–353, 357, 358

photocarcinogenesis, 357–358

seborrheic keratoses, 361

skin cancer, 361–362

ulcers, 363–364

ultraviolet immunosuppression, 358–359

APCs, 359

cytokines, 359

DNA and urocanic acid, 360

nitric oxide, 360–361

T lymphocytes, 359–360

vitamin D, 361

Src family tyrosine phosphatase-1 (SHP-1), 233

*Staphylococcus aureus*, 232

Stem cells

age-associated epigenetic changes, 27–28

hematopoietic stem cells, 25

premature syndromes, 28

regenerative medicine, 31–32

tissue reciprocal effects, 26–27

treatment

autoimmune diseases, 29–30

cardiovascular diseases, 30

cell replacement, 29

gene therapy, 30–31

Huntington's disease, 29

intervention strategy, 29

Parkinson disease, 29

*Streptococcus pneumoniae*, 53

Stress-activated protein kinase (SAPK) family, 330

## T

T cell activation, 184–186

T cell maturation, 184

T cell-mediated immunity

CD4<sup>+</sup> T Cells, 166–167

immunosenescence process

antigenic stimulation, 165

CD28 T cells, 165

innate and adaptive immune system, 162

naïve T cells, 163–164

quantifiable disorder, 168–169

Treg cells activity and effects, 166

life expectancy, 161

memory T cells

bone marrow, 167

reactogenicity, 168

- sj-TREC
    - DNA sequences, 169
    - naïve T cells, 170–171
    - quantitative polymerase chain reaction, 171
  - T cell metabolism. *See* Metabolism
  - T cell repertoire
    - age-associated immune dysfunction
      - memory repertoire, 151–153
      - naïve repertoire, 150–151
    - naïve T cell repertoire, 146–147
  - T cell clonal expansions
    - CD8 + T cells, 147
    - characteristics, 147
    - chronic infection, 148–150
    - functional capacity, 148
  - therapeutic approaches
    - antiviral therapy, 155
    - calorie restriction, 154
    - CMV, 154–155
    - peripheral cells, 154
    - thymic rejuvenation, 153–154
    - vaccination strategies, 153
  - T cells
    - in elderly human, 180–181
    - immune defects
      - autoantibodies, 180
      - B cell functions, 180
      - calcium, 179
      - IgM response, 180
      - naïve CD4<sup>+</sup> cells, 178
      - telomeres, 180
      - thymic involution, 177–178
  - Tetanus-diphtheria-acellular pertussis (Tdap), 237, 238
  - T helper (Th) cells, 244–245
  - Third National Health and Nutrition Examination Survey (NHANES), 297
  - TLRs. *See* Toll-like receptors (TLRs)
  - Toll-like receptors (TLRs), 87–88, 232, 233, 342
    - aged adults, 90–93
    - in cancer
      - HCV-induced hepatocarcinoma, 110–111
      - HMGB1, 112–113
      - immunotherapeutics, 113–114
      - inflammation-associated cancers, 108
      - miRNAs, 112
      - SNPs, 109
      - TLR2, 108, 112
      - TLR4, 108–109, 112
      - TLR agonists, 113–115
      - TLR3 expression, 108
      - TLR9 expression, 109, 110
      - TLR ligands, 112–113
      - TLR7/8 stimulation, 110
    - cardiovascular disease, 102–103
    - cognition and neurodegenerative disease, 116–118
    - DCs, age-associated changes in, 66–67
    - hyporesponsiveness, 93–94
    - in infancy, 88–90
    - inflammaging, 94–97
    - metabolic syndrome, 98–100
  - Total lymphocyte count (TLC), 278
  - Trans-urocanic acid (Trans-UCA), 360
  - T regulatory (Treg) cells
    - CD4<sup>+</sup> T cells, 201
    - effector-memory T cells, 203
    - inflammatory process, 204–205
    - innate and adaptive immune cells, 201
    - iTreg, 201
    - mechanism, 203
    - nTreg, 201
    - suppressive capacity, 203–204
  - Triceps skin fold (TSF), 278
  - Tuberculosis, 235–236
- U**
- Urinary tract infections (UTI), 231
- V**
- Vaccination
    - CMV, 238
    - and exercise, 388–389
    - influenza, 245–247, 252–253
      - antigen dosages, 253–254
      - cytokines, 255–256
      - hospitalization, 253
    - immunogenicity and efficacy, 256–258
    - intra-dermal vaccination, 254–255
    - LAIV, 256
    - MF59-adjuvanted vaccines, 256–258
    - mortality, 253
    - pneumococcal vaccine, 238
  - laboratory evaluation, 237
  - recommended immunizing schedule, 237
  - VZV, 238
- Varicella zoster vaccine (VZV), 236–238
- Virgin olive oil (VOO), 290
- Vitamin A deficiency, 269
- Vitamin B6 deficiency, 269
- Vitamin B9 deficiency, 269–270
- Vitamin B12 deficiency, 269–270
- Vitamin C deficiency, 270
- Vitamin D deficiency, 270
- Vitamin E deficiency, 270
- W**
- West Nile virus (WNV), 97
  - World Health Organization (WHO), 254
- X**
- Xerosis, 363

**Z**

## Zinc

- dietary zinc deficiency, 296–298
- in elderly population
  - MT and IL-6 polymorphisms, zinc supplementation, 303–304
  - zinc status, 298–299
- and immunosenescence, 299–300
- adaptive immunity, 300
  - humoral immunity, 301–302
  - innate immunity, 300–301
  - T-cell functions, 300
- inflammatory/immune response
  - zinc-IL-6 gene interaction, 303
  - zinc-MT gene interaction, 302–303
- mutations in Zip4, 298